Mumbai: Pharmaceutical company, Aurobindo Pharma today said it has received US Food and Drug Administration’s approval to manufacture and market anti-insomnia drug Zolpidem in the US.
The company has received the approval to manufacture and market drug Zolpidem tablets in multiple strengths of 5 mg and 10 mg, Aurobindo Pharma informed the Bombay Stock Exchange.
Zolpidem belongs to the class of medicines, which act on the central nervous system called as “imidazopyridines”. It is the generic version of the brand “Ambien” manufactured and sold by Sanofi Aventis.
The drug is used in short-term treatment of insomnia and enjoys a market of around $2.1 billion in the US.
Recently, Ranbaxy Laboratories and Dr Reddys Laboratories had also received USFDA approval to manufacture and market Zolpidem Tartrate tablets in the US.
The shares of Aurobindo Pharma were trading at Rs683, up 0.10% on the BSE.